Review the 2033 outlook for the metabolism drugs market, highlighting opportunities from dual‑action therapies, oral GLP‑1 innovations, and growing awareness of preventive care for metabolic conditions. https://www.openpr.com/news/4317389/metabolism-drugs-market-to-surpass-usd-14-3bn-by-2033-glp-1